 To compare efficacy and safety of dapagliflozin Â± saxagliptin with glimepiride as add-on to metformin in patients with type 2 diabetes. This 52-week , multicenter , double-blind , active-controlled study ( NCT02471404) randomized ( 1:1:1) patients ( n = 939; HbA Baseline mean age , diabetes duration and HbA Dapagliflozin , saxagliptin and metformin improved glycemic control compared with glimepiride plus metformin; add-on of dapagliflozin alone showed similar efficacy to glimepiride. Both dapagliflozin regimens decreased body<symptom> weight<symptom> and SBP , with lower hypoglycemia incidence compared with glimepiride. This article is protected by copyright. All rights reserved.